Bio-Gene Technology (ASX:BGT) Research & Development: A$1.93 Mil (TTM As of Dec. 2025)


What is Bio-Gene Technology Research & Development?

Bio-Gene Technology ASX:BGT Research & Development is A$1.93 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bio-Gene Technology's Research & Development for the six months ended in Dec. 2025 was A$1.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.93 Mil.

Bio-Gene Technology  (ASX:BGT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bio-Gene Technology Research & Development Related Terms

Bio-Gene Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Research & Development Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 1.68 1.90 1.98 1.07 1.38

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.35 0.54 0.84 1.09

Bio-Gene Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$1.93 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Research & Development of A$1.93 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Research & Development too high?
Bio-Gene Technology's current Research & Development is A$1.93 Mil.
How does Bio-Gene Technology's Research & Development compare to VRTX and REGN?
Bio-Gene Technology's Research & Development of A$1.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Research & Development is A$1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Research & Development of A$1.93 Mil. The current Research & Development is A$1.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Research & Development is A$1.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.